ArticleThe American journal of tropical medicine and hygiene2025
Progressive Disseminated Histoplasmosis with Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haemophagocytic Lymphohistiocytosis Following Severe Erysipelas with EBV Reactivation.Acta dermato-venereologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Histoplasmosis is the most common endemic mycosis in North and Central America, particularly in the Ohio and Mississippi River Valleys. Progressive disseminated histoplasmosis (PDH) occurs in ∼1 in 2,000 acute infections and may present atypically with multiorgan involvement, especially in immunocompromised hosts. We describe a case of PDH complicated by macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH) in a patient with dermatomyositis who was receiving long-term immunosuppressive therapy. She developed two uncommon manifestations of PDH: biopsy-proven cellulitis and intracellular yeasts within neutrophils on a peripheral blood smear. Diagnosis was delayed because of fungal antigen cross-reactivity and overlapping clinical and laboratory features of PDH and MAS/HLH. This case highlights the importance of early recognition, timely treatment, and coordinated multidisciplinary management. Our patient died 17 days after admission, underscoring the high mortality rate of MAS/HLH-associated histoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.